13120.0000 66.00 (0.51%)
NSE Nov 20, 2026 15:31 PM
Volume: 218.9K
 

13120.00
0.51%
SPA Research
On the back of COVID impact, Revenue remained flat YoY at INR 8,574mn. But for COVID impact, revenue would have grown 19%. During Q1FY21, Dixon got approved by ICMR for manufacturing testing devices for 27 diseases including COVID & TB marking its entry into medical electronics segment. However, EBITDA jumped 50% to INR 561mn despite absorbing INR 100mn impact of COVID as well as INR 45mn impact of Forex loss. Gross margins rose by an impressive 340bps to 15.8%. PAT registered a steep increase of 68% to INR 275mn despite COVID impact of INR 70mn during the quarter....
Dixon Technologies (India) Ltd. is trading below its 100 day SMA of 13342.0
More from Dixon Technologies (India) Ltd.
Recommended